Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States (ACR Convergence 2025) - Sep 15, 2025 - Abstract #1044; Pres time: Oct 27, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; "Background/Purpose: Hydroxychloroquine is a cornerstone in the treatment of Systemic Lupus Erythematosus (SLE), while corticosteroids and immunosuppressive agents are employed for moderate to severe disease [1]. The introduction of targeted biologic agents such as Belimumab for active SLE and lupus nephritis (LN), Anifrolumab for moderate to severe active SLE and Voclosporin for active LN, has expanded the therapeutic armamentarium... The rapid growth in spending reflects expanded utilization of biologics (Figure 1). Although average spending per claim showed only modest changes, the substantial rise in spending per beneficiary highlights increased reliance on these newly approved therapies (Figure 2). Patients with severe SLE exhibit elevated rates of inpatient admissions and emergency department utilization, significantly contributing to increased healthcare expenditures [3]."
Clinical • Medicaid • Medicare • Reimbursement • US reimbursement • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|
|
Gunjan Rana1; Mansi Mehta1; Joanne Cunha2
|